Thomas Povsic, MD
Cardiovascular Disease · Durham, NCNPI 1437233327
Payments from drug & device makers
Across 135 payments — averaging $1286.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$125K
- E.r. Squibb & Sons, L.L.C.$19K
- Boehringer Ingelheim International GmbH$8K
- CSL Behring$8K
- Eli Lilly$7K
- Shockwave Medical, Inc$5K
- plus $638 from 2 others
Across 76 payments — averaging $2593.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$197K
What the payments were for
- Consulting fees$15,47666%
- Travel & lodging$6,23626%
- Food & beverage$1,8438%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 79 | $125,250 |
| E.r. Squibb & Sons, L.L.C. | 3 | $19,335 |
| Boehringer Ingelheim International GmbH | 11 | $8,010 |
| CSL Behring | 32 | $7,965 |
| Eli Lilly | 1 | $7,210 |
| Shockwave Medical, Inc | 7 | $5,253 |
| Astrazeneca AB | 1 | $556 |
| Novo Nordisk | 1 | $82 |
How this compares
$173,661 in reported general payments places this provider in the 90th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 29 | $23,238 |
| EliquisApixaban | 22 | $22,779 |
| XareltoRivaroxaban | 20 | $10,824 |
| Ezetimibe | 54 | $1,237 |
| Rosuvastatin Calcium | 78 | $1,087 |
| Metoprolol Succinate | 43 | $780 |
| Nitroglycerin PatchNitroglycerin | 12 | $382 |
| Pantoprazole Sodium | 15 | $343 |
| Carvedilol | 30 | $273 |
| Atorvastatin Calcium | 30 | $268 |
| ClopidogrelClopidogrel Bisulfate | 17 | $212 |
| Losartan Potassium | 17 | $193 |
| Nitroglycerin | 12 | $164 |
| Amlodipine Besylate | 15 | $100 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Durham
- John AlexanderDurham$76.8M
- Christopher GrangerDurham$24.7M
- Jonathan PicciniDurham$14.3M
- Adrian HernandezDurham$13.2M
- Gary FelkerDurham$12.7M
- Robert MentzDurham$6M
- Nishant ShahDurham$3.5M
- Andrew AmbrosyDurham$3.2M
- Michel KhouriDurham$2.4M
- R WilliamsDurham$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.